Evidence map›Paper›PMID 39959404›Full record

ArticleIJTLD open2025

Patient pathway analysis of rifampicin-resistant TB diagnostic and treatment delays.

S Ge, Z Feng, L Lin, R Li, Y Zhang, L Song, A Wang, Y Lan, Y Li, Z Huang and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

S GeDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Z FengDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
L LinDepartment of Tuberculosis, The Third People's Hospital of Bijie, Bijie, China.
R LiDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Y ZhangDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
L SongDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
A WangDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Y LanDepartment of Pneumology and Critical Care Medicine Respiratory Division II, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Y LiDepartment of Tuberculosis, The Third People's Hospital of Liupanshui, Liupanshui, China.
Z HuangDepartment of Tuberculosis, Guiyang Public Health Clinical Centre, Guiyang, China.
C CaiDepartment of Tuberculosis, Guiyang Public Health Clinical Centre, Guiyang, China.
X WangDepartment of Infectious Diseases, The People's Hospital of Anshun, Anshun, China.
Q RuanDepartment of Infectious Diseases, The People's Hospital of Anshun, Anshun, China.
H YuDepartment of Infectious Diseases, The First People's Hospital of Huaihua, Huaihua, China.
M TangDepartment of MDR-TB, Hunan Province Chest Hospital, Changsha, China.
H YiDepartment of MDR-TB, Hunan Province Chest Hospital, Changsha, China.
Y ChenDepartment of Tuberculosis, Hangzhou Red Cross Hospital, Hangzhou, China.
F SunDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Y LiDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
W ZhangDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBarriers to the diagnosis and treatment of rifampicin-resistant TB (RR-TB) have not been fully elucidated. This study aimed to map the diagnostic and treatment delays among patients with RR-TB in China and investigate related factors.

methodsBetween June and July 2023, the diagnostic and treatment pathways of patients with RR-TB were obtained through interviews at eight hospitals across China. Information on the TB service of hospitals was collected via telephone.

resultsNinety-eight patients were included. On average, each patient required 4.6 visits to start RR-TB treatment. The median delay from illness onset to RR-TB treatment was 238.0 days (IQR 85.8-469.2), primarily driven by the delay between TB diagnosis and identifying rifampicin (RIF) resistance (median: 43.5 days, IQR 3.0-160.5). Referral to appropriate hospitals (adjusted hazard ratio [aHR] 2.32; 95% CI 1.37-3.92) or considering drug susceptibility testing (DST) when initiating treatment (aHR 2.56, 95% CI 1.39-4.72) significantly reduced delay between TB diagnosis and identifying RIF resistance, while stigma regarding TB (aHR 0.61, 95% CI 0.38-0.98) was an independent risk factor.

conclusionsPatients with RR-TB experienced substantial delays in identifying RIF resistance. Referring patients to hospitals with molecular DST capabilities and awareness may reduce these delays.

Indexed as

diagnostic delaydrug susceptibility testingrapid molecular testingtreatment delay

Identifiers

PMID39959404
PMCPMC11827674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.